Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market By Treatment Type (BPH Drugs, BPH Devices), Distribution Channel (Institutional Sales, Retail Sales, Online Pharmacies) & Region - Forecast 2022 - 2028
Market Insights on Benign Prostatic Hyperplasia (BPH) Prostate Treatment covering sales outlook, demand forecast and up-to-date key trends
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Outlook (2022-2028)
[252 Pages Report] Standing at a net worth of US$ 30.04 Bn in 2022, the global benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to attain a valuation of US$ 39.5 Bn by the end of 2028. Demand for benign prostatic hyperplasia prostate treatment is projected to rise at a steady CAGR of 4.7% from 2022 to 2028.
|
Benign Prostatic Hyperplasia Prostate Treatment Market Size (2022) |
US$ 30.04 Bn |
|
Projected Market Value (2028) |
US$ 39.5 Bn |
|
Forecast Growth Rate (2022-2028) |
4.7% CAGR |
|
Dominant Distribution Channel |
Institutional Sales - 64.7% |
Worldwide benign prostatic hyperplasia treatment market revenue accounted for 23.8% share in the global cancer treatment market in 2021. Rising preference for minimally-invasive surgeries is anticipated to propel BPH surgical treatment procedure demand over the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
4.57% |
|
H1, 2022 Projected |
4.67% |
|
H1, 2022 Outlook |
4.17% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 50 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 40 ↓ |
The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 50 BPS units. A decline in BPS growth in H1-2022 over H1-2021 by 40 Basis Point Share (BPS) is demonstrated by the market.
The decline in the BPS values is associated with the emergence of urinary tract infections after treatment, increasing patient discomfort and raising healthcare costs, and the susceptibility to kidney damage.
However, with the advent of prostate artery embolization (PAE) procedures for the treatment of benign prostatic hyperplasia, the market is set to gain traction over the forecast period, owed to greater patient satisfaction rates and positive procedural outcomes.
The market is subject to changes as per the regulatory dynamics associated with the macro and industry standards. Key development in the market includes the launch of Optilume drug-coated balloon with enhanced efficacy for benign prostatic hyperplasia treatment.
Demand Analysis of BPH Prostate Treatment Drugs & Devices (2013 to 2021) Vs Future Market Metrics (2022 to 2028)
Increasing incidence of benign prostatic hyperplasia (BPH) is a major factor that is propelling demand for BPH treatment drugs and devices, and the trend has been picking up pace over the past few years. The global BPH prostate treatment market rose at a CAGR of 3.7% from 2013 to 2021.
Increasing focus on healthcare, rising geriatric population, deteriorating lifestyle, poor eating habits, hereditary inheritance of the disease, rising research and development, increasing availability of treatment procedures are some of the major factors influencing BPH treatment market growth.
However, side effects associated with BPH drugs are anticipated to have a restraining effect on the benign prostatic hyperplasia prostate treatment market potential.
High costs associated with BPH surgical treatment procedures are also expected to have a similar hindering effect. But, these factors are expected to favour demand for BPH homeopathy remedies, BPH relief medicine, and benign prostatic hyperplasia natural remedies over the forecast period.
The benign prostatic hyperplasia prostate treatment market is anticipated to expand at a CAGR of 4.7% from 2022 to 2028.
What’s Favouring BPH Treatment Market Potential?
“Rising Incidence of Benign Prostatic Hyperplasia”
Instances of benign prostatic hyperplasia have substantially risen and are expected to keep rising over the forecast period as well. The growing geriatric population across the world is a major factor that is governing the BPH treatment market potential.
BPH surgical treatment procedures are expected to see a rise as patient preference for minimally invasive surgeries increases.
Find your sweet spots for generating winning opportunities in this market.
What is the Outlook for BPH Drug Treatment?
“Rising Awareness about Side-Effects of BPH Drugs to Restrain Market Growth”
BPH drugs have been extensively used for benign prostatic hyperplasia treatment for quite a while now but now as the awareness for long-term side-effects of these drugs increases, their adoption is expected to see a drop and negatively affect the overall market growth.
BPH homeopathy remedies, benign prostatic hyperplasia home remedies, and benign prostatic hyperplasia natural remedies are expected to benefit from the aforementioned factor and are anticipated to see an increase in adoption from the growing patient pool across the world.
What is the Regional Outlook for the BPH Prostate Treatment Industry?
“North America to Hold Dominant Market Share through 2028”
This global BPH prostate treatment devices and drugs industry survey details market stance across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The North America BPH treatment market holds a dominant market share and is expected to maintain this outlook through 2028. Rising instances of benign prostatic hyperplasia, increasing geriatric population, and the presence of key benign prostatic hyperplasia prostate treatment providers are major factors influencing the market potential in this region.
The Europe BPH prostate treatment market is also expected to have a bright outlook over the forecast period. Increasing focus on healthcare and rising research activity in this region are expected to be major trends in the Europe BPH treatment industry through 2028.
East Asia and South Asia are expected to provide lucrative opportunities for BPH treatment over the forecast period. The rising geriatric population in India, China, and Japan is expected to be the most prominent trend in these regions and propel the demand for BHP treatment procedures. BHP drugs are expected to be more popular than BHP surgical treatment procedures in these regions.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country-wise Analysis
Why Should BPH Treatment Providers Focus on the U.S.?
“Rising Geriatric Population to Boost Demand for BPH Treatment Drugs & Devices”
The U.S. is anticipated to see a high demand for BPH treatment owing to the increasing incidence of benign prostatic hyperplasia. The nation is seeing a rise in its geriatric population which is more prone to this condition and hence is a highly lucrative market for BPH treatment providers.
Rising research and development activities and availability of BHT surgical treatment are also expected to influence market potential in the U.S.
What is the Outlook for BPH Treatment in India?
“Ayurveda Medicines for BPH Symptoms to See High Demand”
India is seeing a gradual increase in its geriatric population and this is expected to result in an increase in cases of benign prostatic hyperplasia. However, the popularity of Ayurveda in the nation is expected to propel sales of Ayurveda medicines for BPH symptoms, and also is expected to favor demand for benign prostatic hyperplasia natural remedies.
This will drive growth of BPH prostate treatment drug and device suppliers in the country.
Category-wise Analysis
Which Distribution Channel Holds a Dominant Market Outlook?
“High Institutional Sales of BPH Treatment Devices & Drugs”
Among all distribution channels, the institutional sales channel is expected to lead the market and currently accounts for a major market share of 64.7% in the global benign prostatic hyperplasia prostate treatment space. Increasing number of minimally invasive surgeries performed in hospitals and specialty clinics are expected to boost institutional sales segment market share through 2028.
Meanwhile, BPH prostate treatment drug retail sales and online pharmacies segments hold market shares of 26.7% and 8.6%, respectively, in the global BPH treatment industry at present.
COVID-19 Crisis Survey
Sudden emergence of the COVID-19 pandemic took the world by shock and had an adverse impact on all healthcare procedures and treatments, as lack of resources during the pandemic didn’t allow healthcare facilities to focus on these treatments.
Facilities were overloaded with high cases of COVID-19 infections across the world and BPH prostate treatment procedures were overlooked which resulted in a negative trend for benign prostatic hyperplasia (BPH) prostate treatment market.
However, BPH homeopathy remedies, BPH relief medicines, benign prostatic hyperplasia over-the-counter medication, and other alternate treatments saw good growth in demand in the pandemic era.
The BPH treatment systems market is anticipated to make a steady comeback in the post-pandemic era as the coronavirus infection load from healthcare facilities is lessened and they can focus on the treatment of other conditions as well.
Benign prostatic hyperplasia natural remedies are expected to see a substantial rise in popularity in the post-pandemic era as awareness about over-the-counter BPH medication side effects increases.
Competitive Landscape
BPH prostate treatment device and drug manufacturers are investing in research & development to come up with novel treatments to offer better treatment opportunities for people suffering from the disease.
- In March 2022, ProVerum, an Irish medtech firm, announced that it had raised around US$ 33 Mn for the clinical trials of its novel treatment for benign prostatic hyperplasia, which is a common condition in aging men.
BPH Prostate Treatment Industry Report Scope
|
Attribute |
Details |
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
|
|
Key Counties Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Segments of BPH Prostate Treatment Industry Survey
BPH Prostate Treatment Market by Treatment Type:
- BPH Drugs
- Alpha Blockers
- 5-Aplha Reductase Inhibitors
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Muscarinic Receptor Antagonist (MRA)
- Combination Drug
- BPH Devices
- Prostatic Stents
- Suture Base Implant Systems
- Transurethral RF Thermal Therapy Devices
BPH Prostate Treatment Market by Distribution Channel:
- Institutional Sales
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
BPH Prostate Treatment Market by Region:
- North America BPH Prostate Treatment Market
- Latin America BPH Prostate Treatment Market
- Europe BPH Prostate Treatment Market
- East Asia BPH Prostate Treatment Market
- South Asia & Pacific BPH Prostate Treatment Market
- Middle East & Africa (MEA) BPH Prostate Treatment Market
Frequently Asked Questions
What valuation does the benign prostatic hyperplasia (BPH) prostate treatment market enjoy in 2022?
In 2022, the global benign prostatic hyperplasia (BPH) prostate treatment market stands at a net worth of US$ 30.04 Bn.
What is the estimated valuation for benign prostatic hyperplasia prostate treatment by 2028?
The BPH prostate treatment market is predicted to attain a valuation of US$ 39.5 Bn by 2028.
Which distribution channel holds the largest market share?
Institutional sales account for a dominant market share of 64.7% in 2022.
Which key players are profiled in this benign prostatic hyperplasia (BPH) prostate treatment industry analysis?
Key market players are Pfizer Inc., NxThera Inc., NeoTract Inc., Sanofi S.A, GlaxoSmithKline Plc., and Allergan Plc.
In terms of CAGR, how is the benign prostatic hyperplasia prostate treatment market predicted to rise?
From 2022 to 2028, the benign prostatic hyperplasia prostate treatment industry is estimated to evolve at a CAGR of 4.7%.
Table of Content
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. Technology Roadmap 1.4. FMI Analysis and Recommendations 2. Market Introduction 2.1. Market Introduction 2.2. Market Taxonomy 2.3. Market Definition 2.4. Inclusions and Exclusions 3. Benign Prostatic Hyperplasia Prostate Treatment Market Opportunity Analysis 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 4. Market Background 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Restraints 4.1.3. Key Trends 5. Key Inclusions 5.1. Pipeline Analysis 5.2. Prevalence and Treatment Seeking Population Analysis 6. Global Economic Outlook 6.1. Gross Domestic Product by Region & Country, 2006 – 2021 7. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Region 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2021 7.2.1. North America 7.2.2. Latin America 7.2.3. Europe 7.2.4. South Asia 7.2.5. East Asia 7.2.6. Oceania 7.2.7. The Middle East and Africa 7.2.8. Emerging Countries 7.3. Market Size (US$ Mn) Forecast By Region, 2022–2028 7.4. Market Attractiveness Analysis by Region 8. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type 8.1. Introduction 8.2. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 8.2.1. Drugs 8.2.1.1. Alpha Blockers 8.2.1.2. 5-alpha Reductase Inhibitors 8.2.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 8.2.1.4. Muscarinic Receptor Antagonist (MRA) 8.2.1.5. Combination Drug 8.2.2. Device 8.2.2.1. Prostatic Stents 8.2.2.2. Suture Base Implant Systems 8.2.2.3. Transurethral RF Thermal Therapy Devices 8.3. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 8.4. Market Attractiveness Analysis by Treatment Type 9. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channels 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 9.2.1. Institutional Sales 9.2.1.1. Hospital 9.2.1.2. Ambulatory Surgical Centers 9.2.1.3. Specialty Clinics 9.2.2. Retail Sales 9.2.2.1. Retail Pharmacies 9.2.2.2. Drug Stores 9.2.3. Online Pharmacies 9.3. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 9.4. Market Attractiveness Analysis by Distribution Channels 10. North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2021 10.2.1. U.S. 10.2.2. Canada 10.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 10.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 10.4.1. Drugs 10.4.1.1. Alpha Blockers 10.4.1.2. 5-alpha Reductase Inhibitors 10.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 10.4.1.4. Muscarinic Receptor Antagonist (MRA) 10.4.1.5. Combination Drug 10.4.2. Device 10.4.2.1. Prostatic Stents 10.4.2.2. Suture Base Implant Systems 10.4.2.3. Transurethral RF Thermal Therapy Devices 10.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 10.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 10.6.1. Institutional Sales 10.6.1.1. Hospital 10.6.1.2. Ambulatory Surgical Centers 10.6.1.3. Specialty Clinics 10.6.2. Retail Sales 10.6.2.1. Retail Pharmacies 10.6.2.2. Drug Stores 10.6.3. Online Pharmacies 10.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 10.8. Market Attractiveness Analysis 10.8.1. By Country 10.8.2. By Treatment Type 10.8.3. By Distribution Channel 10.9. Market Size and Forecast Factors 10.10. Key Intensity Mapping 11. Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) By Country, 2013–2021 11.2.1. Brazil 11.2.2. Mexico 11.2.3. Rest of Latin America 11.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 11.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 11.4.1. Drugs 11.4.1.1. Alpha Blockers 11.4.1.2. 5-alpha Reductase Inhibitors 11.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 11.4.1.4. Muscarinic Receptor Antagonist (MRA) 11.4.1.5. Combination Drug 11.4.2. Device 11.4.2.1. Prostatic Stents 11.4.2.2. Suture Base Implant Systems 11.4.2.3. Transurethral RF Thermal Therapy Devices 11.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 11.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 11.6.1. Institutional Sales 11.6.1.1. Hospital 11.6.1.2. Ambulatory Surgical Centers 11.6.1.3. Specialty Clinics 11.6.2. Retail Sales 11.6.2.1. Retail Pharmacies 11.6.2.2. Drug Stores 11.6.3. Online Pharmacies 11.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 11.8. Market Attractiveness Analysis 11.8.1. By Country 11.8.2. By Treatment Type 11.8.3. By Distribution Channel 11.9. Market Size and Forecast Factors 11.10. Key Intensity Mapping 12. Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2021 12.2.1. Germany 12.2.2. U.K. 12.2.3. France 12.2.4. Italy 12.2.5. Russia 12.2.6. Spain 12.2.7. Rest of Europe 12.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 12.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 12.4.1. Drugs 12.4.1.1. Alpha Blockers 12.4.1.2. 5-alpha Reductase Inhibitors 12.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 12.4.1.4. Muscarinic Receptor Antagonist (MRA) 12.4.1.5. Combination Drug 12.4.2. Device 12.4.2.1. Prostatic Stents 12.4.2.2. Suture Base Implant Systems 12.4.2.3. Transurethral RF Thermal Therapy Devices 12.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 12.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 12.6.1. Institutional Sales 12.6.1.1. Hospital 12.6.1.2. Ambulatory Surgical Centers 12.6.1.3. Specialty Clinics 12.6.2. Retail Sales 12.6.2.1. Retail Pharmacies 12.6.2.2. Drug Stores 12.6.3. Online Pharmacies 12.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 12.8. Market Attractiveness Analysis 12.8.1. By Country 12.8.2. By Treatment Type 12.8.3. By Distribution Channel 12.9. Market Size and Forecast Factors 12.10. Key Intensity Mapping 13. South Asia Benign Prostatic Hyperplasia Prostate Treatment Analysis 2013–2021 and Forecast 2022–2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) By Country, 2013–2021 13.2.1. India 13.2.2. Thailand 13.2.3. Indonesia 13.2.4. Malaysia 13.2.5. Rest of South Asia 13.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 13.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 13.4.1. Drugs 13.4.1.1. Alpha Blockers 13.4.1.2. 5-alpha Reductase Inhibitors 13.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 13.4.1.4. Muscarinic Receptor Antagonist (MRA) 13.4.1.5. Combination Drug 13.4.2. Device 13.4.2.1. Prostatic Stents 13.4.2.2. Suture Base Implant Systems 13.4.2.3. Transurethral RF Thermal Therapy Devices 13.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 13.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 13.6.1. Institutional Sales 13.6.1.1. Hospital 13.6.1.2. Ambulatory Surgical Centers 13.6.1.3. Specialty Clinics 13.6.2. Retail Sales 13.6.2.1. Retail Pharmacies 13.6.2.2. Drug Stores 13.6.3. Online Pharmacies 13.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 13.8. Market Attractiveness Analysis 13.8.1. By Country 13.8.2. By Treatment Type 13.8.3. By Distribution Channel 13.9. Market Size and Forecast Factors 13.10. Key Intensity Mapping 14. East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 14.1. Introduction 14.2. Historical Market Size (US$ Mn) By Country, 2013–2021 14.2.1. China 14.2.2. Japan 14.2.3. South Korea 14.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 14.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2021 14.4.1. Drugs 14.4.1.1. Alpha Blockers 14.4.1.2. 5-alpha Reductase Inhibitors 14.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 14.4.1.4. Muscarinic Receptor Antagonist (MRA) 14.4.1.5. Combination Drug 14.4.2. Device 14.4.2.1. Prostatic Stents 14.4.2.2. Suture Base Implant Systems 14.4.2.3. Transurethral RF Thermal Therapy Devices 14.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 14.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2021 14.6.1. Institutional Sales 14.6.1.1. Hospital 14.6.1.2. Ambulatory Surgical Centers 14.6.1.3. Specialty Clinics 14.6.2. Retail Sales 14.6.2.1. Retail Pharmacies 14.6.2.2. Drug Stores 14.6.3. Online Pharmacies 14.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 14.8. Market Attractiveness Analysis 14.8.1. By Country 14.8.2. By Treatment Type 14.8.3. By Distribution Channel 14.9. Market Size and Forecast Factors 14.10. Key Intensity Mapping 15. Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 15.1. Introduction 15.2. Historical Market Size (US$ Mn) By Country, 2013–2021 15.2.1. Australia 15.2.2. New Zealand 15.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 15.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021 15.4.1. Drugs 15.4.1.1. Alpha Blockers 15.4.1.2. 5-alpha Reductase Inhibitors 15.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 15.4.1.4. Muscarinic Receptor Antagonist (MRA) 15.4.1.5. Combination Drug 15.4.2. Device 15.4.2.1. Prostatic Stents 15.4.2.2. Suture Base Implant Systems 15.4.2.3. Transurethral RF Thermal Therapy Devices 15.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 15.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021 15.6.1. Institutional Sales 15.6.1.1. Hospital 15.6.1.2. Ambulatory Surgical Centers 15.6.1.3. Specialty Clinics 15.6.2. Retail Sales 15.6.2.1. Retail Pharmacies 15.6.2.2. Drug Stores 15.6.3. Online Pharmacies 15.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 15.8. Market Attractiveness Analysis 15.8.1. By Country 15.8.2. By Treatment Type 15.8.3. By Distribution Channel 15.9. Market Size and Forecast Factors 15.10. Key Intensity Mapping 16. MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 16.1. Introduction 16.2. Historical Market Size (US$ Mn) By Country, 2013–2021 16.2.1. GCC Countries 16.2.2. Turkey 16.2.3. South Africa 16.2.4. North Africa 16.2.5. Rest of MEA 16.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 16.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021 16.4.1. Drugs 16.4.1.1. Alpha Blockers 16.4.1.2. 5-alpha Reductase Inhibitors 16.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 16.4.1.4. Muscarinic Receptor Antagonist (MRA) 16.4.1.5. Combination Drug 16.4.2. Device 16.4.2.1. Prostatic Stents 16.4.2.2. Suture Base Implant Systems 16.4.2.3. Transurethral RF Thermal Therapy Devices 16.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 16.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021 16.6.1. Institutional Sales 16.6.1.1. Hospital 16.6.1.2. Ambulatory Surgical Centers 16.6.1.3. Specialty Clinics 16.6.2. Retail Sales 16.6.2.1. Retail Pharmacies 16.6.2.2. Drug Stores 16.6.3. Online Pharmacies 16.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 16.8. Market Attractiveness Analysis 16.8.1. By Country 16.8.2. By Treatment Type 16.8.3. By Distribution Channel 16.9. Market Size and Forecast Factors 16.10. Key Intensity Mapping 17. Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2021 and Forecast 2022–2028 17.1. Introduction 17.2. Historical Market Size (US$ Mn) By Country, 2013–2021 17.2.1. China 17.2.2. Brazil 17.2.3. South Africa 17.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 17.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2021 17.4.1. Drugs 17.4.1.1. Alpha Blockers 17.4.1.2. 5-alpha Reductase Inhibitors 17.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 17.4.1.4. Muscarinic Receptor Antagonist (MRA) 17.4.1.5. Combination Drug 17.4.2. Device 17.4.2.1. Prostatic Stents 17.4.2.2. Suture Base Implant Systems 17.4.2.3. Transurethral RF Thermal Therapy Devices 17.5. Market Size (US$ Mn) Forecast By Treatment Type, 2022–2028 17.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2021 17.6.1. Institutional Sales 17.6.1.1. Hospital 17.6.1.2. Ambulatory Surgical Centers 17.6.1.3. Specialty Clinics 17.6.2. Retail Sales 17.6.2.1. Retail Pharmacies 17.6.2.2. Drug Stores 17.6.3. Online Pharmacies 17.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2022–2028 17.8. Market Attractiveness Analysis 17.8.1. By Country 17.8.2. By Treatment Type 17.8.3. By Distribution Channel 17.9. Market Size and Forecast Factors 17.10. Key Intensity Mapping 18. Competitive Landscape 18.1. Competition Dashboard 18.2. Company Deep Dive 18.2.1. Pfizer, Inc. 18.2.1.1. Company Overview 18.2.1.2. Product Portfolio 18.2.1.3. Key Financials and Y-O-Y Growth 18.2.1.4. Key Development and Strategy 18.2.2. NxThera Inc. 18.2.2.1. Company Overview 18.2.2.2. Product Portfolio 18.2.2.3. Key Financials and Y-O-Y Growth 18.2.2.4. Key Development and Strategy 18.2.3. NeoTract, Inc. 18.2.3.1. Company Overview 18.2.3.2. Product Portfolio 18.2.3.3. Key Financials and Y-O-Y Growth 18.2.3.4. Key Development and Strategy 18.2.4. Sanofi S.A. 18.2.4.1. Company Overview 18.2.4.2. Product Portfolio 18.2.4.3. Key Financials and Y-O-Y Growth 18.2.4.4. Key Development and Strategy 18.2.5. GlaxoSmithKline plc. 18.2.5.1. Company Overview 18.2.5.2. Product Portfolio 18.2.5.3. Key Financials and Y-O-Y Growth 18.2.5.4. Key Development and Strategy 18.2.6. Allergan plc. 18.2.6.1. Company Overview 18.2.6.2. Product Portfolio 18.2.6.3. Key Financials and Y-O-Y Growth 18.2.6.4. Key Development and Strategy 18.2.7. Teva Pharmaceutical Industries Ltd 18.2.7.1. Company Overview 18.2.7.2. Product Portfolio 18.2.7.3. Key Financials and Y-O-Y Growth 18.2.7.4. Key Development and Strategy 18.2.8. Mylan N.V. 18.2.8.1. Company Overview 18.2.8.2. Product Portfolio 18.2.8.3. Key Financials and Y-O-Y Growth 18.2.8.4. Key Development and Strategy 18.2.9. Eli Lilly and Company 18.2.9.1. Company Overview 18.2.9.2. Product Portfolio 18.2.9.3. Key Financials and Y-O-Y Growth 18.2.9.4. Key Development and Strategy 18.2.10. Cardinal Health Inc. 18.2.10.1. Company Overview 18.2.10.2. Product Portfolio 18.2.10.3. Key Financials and Y-O-Y Growth 18.2.10.4. Key Development and Strategy 19. Assumptions and Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Expenditure on Health (% of GDP) by Country, 2016-2021 Table 2: Expenditure on Health (% of GDP) by Country, 2016-2021 Table 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region Table 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 6: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 7: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 8: North America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 9: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 10: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 11: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 12: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 13: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 14: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 15: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 16: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 17: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 18: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 19: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 20: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 21: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 22: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 23: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 24: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country Table 25: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 26: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 27: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 28: China Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 29: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 30: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel Table 31: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Treatment Table 32: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 2: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 3: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 4: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 5: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 6: Global Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 7a: World GDP (Nominal) by Selected Economies, 2021 Figure 7b: Global Healthcare Expenditure in US$ Bn (2013–2020) Figure 8: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Region, 2022E & 2028F Figure 9: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Region, 2022E Figure 10: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Treatment, 2022E & 2028F Figure 11: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 12: Global Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Distribution Channel, 2022E & 2028F Figure 13: Global Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 14: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 15: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 16: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 17: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 18: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 19: North America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 019: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 20: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 21: North America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 22: North America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 23: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 24: North America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 25: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 26: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 27: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 28: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 29: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 30: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 31: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 32: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 33: Latin America Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 34: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 35: Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 36: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 37: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 38: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 39: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 40: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 41: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 42: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 43: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 44: Europe Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 45: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 46: Europe Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 47: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 48: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 49: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 50: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 51: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 52: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 53: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 54: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 55: South Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 56: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 57: South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 58: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 59: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 60: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 61: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 62: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 63: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 64: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 65: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 66: East Asia Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 67: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 68: East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 69: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 70: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 71: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 72: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 73: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 74: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 75: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 76: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 77: Oceania Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 78: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 79: Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 80: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 81: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 82: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 83: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 84: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 85: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 86: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 87: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 88: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatments Market Attractiveness Analysis, By Country, 2022E Figure 89: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 90: Middle-East & Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 91: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value Share (2021A) Figure 92: Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Value (US$ Mn), By Key Countries, 2021A-2028E Figure 93: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 94: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 95: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 96: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 97: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 98: China Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 99: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 100: China Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 101: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 102: China Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 103: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 104: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 105: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 106: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 107: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 108: Brazil Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 110: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 111: Brazil Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E Figure 112: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Treatment, 2021A Figure 113: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Drugs, 2021A Figure 114: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Devices, 2021A Figure 115: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Distribution Channel, 2021A Figure 116: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Institutional Sales, 2021A Figure 117: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Revenue Share by Retail Sales, 2021A Figure 118: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) Analysis, 2013–2021 Figure 119: South Africa Benign Prostatic Hyperplasia Prostate Treatments Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028 Figure 120: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Treatment, 2022E Figure 121: South Africa Benign Prostatic Hyperplasia Prostate Treatment Market Attractiveness Analysis, By Distribution Channel, 2022E
Recommendations
Explore Healthcare Insights
View Reports
